Paolo Tarantino: The longest follow up to date of a metastatic trastuzumab trial.

Paolo Tarantino, a clinical research fellow at the Dana-Farber Cancer Institute, shared the following insight on X/Twitter:

“The longest follow-up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study were still alive: click here.

How to recognize & increase the rate of long-term survivors? Click here.”

Source: Paolo Tarantino/Twitter